Table II.

Expression frequency of individual markers of B-cell differentiation in 51 HIV-infected and 116 HIV-uninfected individuals with DLBCL.

Protein*	HIV-infected		HIV-uninfected		p-Value†
	n/total	(%)	n/total	(%)
Germinal center B-cell markers
BCL6	14/50	(28)	53/116	(46)	0.039
CD10 (MME)	13/49	(27)	42/113	(37)	0.210
GCET1 (SERPINA9)	6/51	(12)	31/116	(27)	0.042
LM02	22/44	(50)	69/114	(61)	0.282
Activated B-cell markers
BCL2	24/50	(48)	67/116	(58)	0.308
FOXP1	31/50	(62)	53/114	(46)	0.090
CD138(SDC1)	5/49	(10)	5/114	(4)	0.169
MUM1 (IRF4)	35/51	(69)	55/115	(48)	0.018
TP53	6/51	(12)	14/116	(12)	1.000

HIV, human immunodeficiency virus; DLBCL, diffuse large B-cell lymphoma.

^*Primary antibodies included BCL6 clone PG-B6p Dako7211, CD10 clone 56C6 Dako M7308, GCET1 courtesy of Dr. Miguel Piris (Santander, Spain), LMO2 clone ab82090 Abcam, BCL2 clone 124 Dako M0887, FOXP1 clone #3210-1 EPITOMICS, CD138 clone MI15 Dako M7228, MUM1 clone Dako M7259 and p53 clone D07 M7001. Secondary antibodies were derived from the Flex Kit from Dako for all except GCET1, LMO2 and FOXP1, for which we used EnVision + polymer from Dako. Antigen retrieval was done using High Ph (Dako) for all antibodies except LMO2 and FOXP1, for which we used DIVA buffer (Biocare). Appropriate positive and negative controls were included in each run.

^†p-Value derived from Fisher's exact test.